Cooper Companies (NASDAQ:COO) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Cooper Companies (NASDAQ:COO) had its target price upped by investment analysts at JPMorgan Chase & Co. from $66.00 to $78.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “neutral” rating on the medical device company’s stock. JPMorgan Chase & Co.‘s target price suggests a potential downside of 5.75% from the stock’s previous close.

Several other equities research analysts have also recently issued reports on the company. Mizuho set a $100.00 price objective on Cooper Companies and gave the stock an “outperform” rating in a report on Friday. Robert W. Baird increased their target price on Cooper Companies from $85.00 to $98.00 and gave the stock an “outperform” rating in a research report on Friday. Needham & Company LLC reissued a “buy” rating and issued a $100.00 price target (up from $94.00) on shares of Cooper Companies in a research note on Friday. The Goldman Sachs Group set a $64.00 price objective on shares of Cooper Companies and gave the company a “sell” rating in a research note on Wednesday, October 1st. Finally, Stifel Nicolaus set a $95.00 price objective on shares of Cooper Companies in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $89.54.

Cooper Companies Trading Up 7.4%

Shares of NASDAQ COO traded up $5.73 during midday trading on Friday, reaching $82.76. 2,887,618 shares of the stock were exchanged, compared to its average volume of 2,408,847. The stock has a 50 day moving average price of $72.01 and a 200-day moving average price of $71.74. The company has a current ratio of 2.12, a quick ratio of 1.24 and a debt-to-equity ratio of 0.29. The company has a market capitalization of $16.45 billion, a P/E ratio of 40.88, a P/E/G ratio of 1.87 and a beta of 1.05. Cooper Companies has a 52-week low of $61.78 and a 52-week high of $101.53.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Thursday, December 4th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.11 by $0.04. Cooper Companies had a net margin of 10.08% and a return on equity of 9.82%. The business had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the prior year, the firm posted $1.04 earnings per share. The company’s quarterly revenue was up 4.6% compared to the same quarter last year. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. Equities research analysts expect that Cooper Companies will post 3.98 earnings per share for the current fiscal year.

Cooper Companies declared that its board has authorized a stock repurchase plan on Wednesday, September 17th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical device company to repurchase up to 15.4% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.

Insider Activity

In other Cooper Companies news, Director Lawrence Erik Kurzius bought 2,000 shares of the company’s stock in a transaction that occurred on Monday, September 29th. The stock was purchased at an average price of $68.39 per share, with a total value of $136,780.00. Following the transaction, the director owned 5,777 shares in the company, valued at $395,089.03. This trade represents a 52.95% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 1.98% of the company’s stock.

Institutional Investors Weigh In On Cooper Companies

Several institutional investors have recently bought and sold shares of the business. Bell Investment Advisors Inc increased its position in shares of Cooper Companies by 106.3% in the third quarter. Bell Investment Advisors Inc now owns 425 shares of the medical device company’s stock worth $29,000 after acquiring an additional 219 shares in the last quarter. Zions Bancorporation National Association UT purchased a new stake in Cooper Companies during the 1st quarter worth $33,000. J.Safra Asset Management Corp boosted its position in Cooper Companies by 204.8% during the 2nd quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company’s stock worth $36,000 after purchasing an additional 340 shares during the period. CYBER HORNET ETFs LLC acquired a new stake in Cooper Companies in the 2nd quarter valued at $36,000. Finally, GKV Capital Management Co. Inc. purchased a new position in Cooper Companies in the first quarter valued at about $40,000. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.